OncoMatch/Clinical Trials/NCT04204850
Cabozantinib to Treat Recurrent Liver Cancer Post Transplant
Is NCT04204850 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Cabozantinib for hepatocellular carcinoma.
Treatment: Cabozantinib — This is a phase 2 study that will assess the investigational drug, cabozantinib, in patients with liver cancer (specifically hepatocellular carcinoma) and who had received a liver transplant as a part of curative care, but the cancer has come back (recurred). The purpose of this study is to see how useful cabozantinib is in controlling the disease of these patients. Cabozantinib blocks the function of various proteins found on the surface of the body's cells (called receptor tyrosine kinases) that are important in the development of cancer tumors. All participants will receive cabozantinib until they are no longer receiving benefit from the study drug or they experience an intolerable side effect.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: liver transplant — curative
Previously underwent a liver transplant as a curative treatment for hepatocellular carcinoma (HCC).
Cannot have received: cabozantinib (cabozantinib)
No prior treatment with cabozantinib.
Lab requirements
Blood counts
Normal organ and marrow function
Kidney function
Requirement for hemodialysis or peritoneal dialysis [excluded]
Liver function
Patients with a grade >= 2 elevated liver enzymes who are suspected of cellular rejection will undergo biopsy. Patients diagnosed with cellular rejection in the biopsy sample using the Banff schema are ineligible.
Cardiac function
Adequate cardiac function
Normal organ and marrow function. Adequate cardiac function. Patients with a grade >= 2 elevated liver enzymes who are suspected of cellular rejection will undergo biopsy. Patients diagnosed with cellular rejection in the biopsy sample using the Banff schema are ineligible. Requirement for hemodialysis or peritoneal dialysis [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify